Zyban Side Effects


Zyban has been studied thoroughly in clinical trials. In these studies, side effects reported by a group of people taking the drug are documented and are then compared to side effects reported by another group not taking the medicine. This way, it is possible to see what side effects occur, how often they appear, and how they compare to the group not taking the medicine.
Based on these studies, the most common side effects of Zyban include:
  • Insomnia — in up to 40 percent of people (see Zyban and Insomnia)
  • An irritated or runny nose — up to 12 percent
  • Dry mouth — up to 11 percent (see Zyban and Dry Mouth)
  • Dizziness — up to 10 percent
  • Nausea — up to 9 percent
  • Trouble concentrating — up to 9 percent
  • Constipation — up to 8 percent
  • Joint pain — up to 5 percent
  • Unusual dreams — up to 5 percent
  • Muscle pain — up to 4 percent
  • Diarrhea — up to 4 percent
  • Nervousness — up to 4 percent.
Some other common Zyban side effects (occurring in 1 to 3 percent of people) include:


Because medications such as Zyban have potential dangers and side-effects, the full text from the Zyban web-site quoted here:


ZYBAN is contraindicated in patients with a seizure disorder.
ZYBAN is contraindicated in patients treated with WELLBUTRIN, WELLBUTRIN SR, or
any other medications that contain bupropion because the incidence of seizure is dose dependent.
ZYBAN is contraindicated in patients with a current or prior diagnosis of bulimia or anorexia
nervosa because of a higher incidence of seizures noted in patients treated for bulimia with the
immediate-release formulation of bupropion.
ZYBAN is contraindicated in patients undergoing abrupt discontinuation of alcohol or
sedatives (including benzodiazepines).
The concurrent administration of ZYBAN and a monoamine oxidase (MAO) inhibitor is
contraindicated. At least 14 days should elapse between discontinuation of an MAO inhibitor and
initiation of treatment with ZYBAN.
ZYBAN is contraindicated in patients who have shown an allergic response to bupropion or
the other ingredients that make up ZYBAN.
Patients should be made aware that ZYBAN contains the same active ingredient found
in WELLBUTRIN and WELLBUTRIN SR used to treat depression, and that ZYBAN
should not be used in combination with WELLBUTRIN, WELLBUTRIN SR, or any other
medications that contain bupropion.
Because the use of bupropion is associated with a dose-dependent risk of seizures,
clinicians should not prescribe doses over 300 mg/day for smoking cessation. The risk of
seizures is also related to patient factors, clinical situation, and concurrent medications,
which must be considered in selection of patients for therapy with ZYBAN. ZYBAN should
be discontinued and not restarted in patients who experience a seizure while on treatment.
• Dose: For smoking cessation, doses above 300 mg/day should not be used. The seizure
rate associated with doses of sustained-release bupropion up to 300 mg/day is
approximately 0.1% (1/1,000). This incidence was prospectively determined during an
8-week treatment exposure in approximately 3,100 depressed patients. Data for the
immediate-release formulation of bupropion revealed a seizure incidence of
approximately 0.4% (4/1,000) in depressed patients treated at doses in a range of 300 to
450 mg/day. In addition, the estimated seizure incidence increases almost tenfold
between 450 and 600 mg/day.
• Patient factors: Predisposing factors that may increase the risk of seizure with
bupropion use include history of head trauma or prior seizure, central nervous system
(CNS) tumor, the presence of severe hepatic cirrhosis, and concomitant medications
that lower seizure threshold.
• Clinical situations: Circumstances associated with an increased seizure risk include,
among others, excessive use of alcohol or sedatives (including benzodiazepines);
addiction to opiates, cocaine, or stimulants; use of over-the-counter stimulants and
anorectics; and diabetes treated with oral hypoglycemics or insulin.
• Concomitant medications: Many medications (e.g., antipsychotics, antidepressants,
theophylline, systemic steroids) are known to lower seizure threshold.
Recommendations for Reducing the Risk of Seizure: Retrospective analysis of clinical
experience gained during the development of bupropion suggests that the risk of seizure
may be minimized if
• the total daily dose of ZYBAN does not exceed 300 mg (the maximum recommended
dose for smoking cessation), and
• the recommended daily dose for most patients (300 mg/day) is administered in divided
doses (150 mg twice daily).
• No single dose should exceed 150 mg to avoid high peak concentrations of bupropion
and/or its metabolites.
ZYBAN should be administered with extreme caution to patients with a history of
seizure, cranial trauma, or other predisposition(s) toward seizure, or patients treated with
other agents (e.g., antipsychotics, antidepressants, theophylline, systemic steroids, etc.) that
lower seizure threshold.
Hepatic Impairment: ZYBAN should be used with extreme caution in patients with severe
hepatic cirrhosis. In these patients a reduced frequency of dosing is required, as peak
bupropion levels are substantially increased and accumulation is likely to occur in such
patients to a greater extent than usual. The dose should not exceed 150 mg every other day


You can get more complete information at the official Zyban website: http://www.zyban.com